Amylin

Pramlintide: How It Complements Insulin

13 min read|March 25, 2026

Amylin

3 mechanisms

Pramlintide controls postprandial glucose through three distinct pathways insulin cannot: glucagon suppression, gastric emptying delay, and central satiety signaling.

Hay et al., Pharmacological Reviews, 2015

View as image

Insulin lowers blood glucose by driving sugar into cells. But insulin alone cannot solve the problem of postprandial glucose spikes, the sharp rises in blood sugar that occur after meals. In healthy physiology, the pancreatic beta cells co-secrete two hormones with every meal: insulin and amylin. Insulin handles glucose uptake. Amylin handles everything else: it suppresses postmeal glucagon release, slows gastric emptying to moderate the rate of glucose entering the bloodstream, and signals satiety to the brain.

In type 1 diabetes, beta cell destruction eliminates both hormones. In advanced type 2 diabetes, amylin secretion is severely impaired. Replacing only insulin addresses half the glucoregulatory picture. Pramlintide (brand name Symlin), a synthetic analog of human amylin approved by the FDA in 2005, fills the other half.

Key Takeaways

Pramlintide is the only FDA-approved amylin analog; it addresses three postprandial glucose control mechanisms that insulin alone cannot: glucagon suppression, gastric emptying delay, and satiety signaling (Hay et al., 2015)
In a head-to-head study, pramlintide suppressed meal-stimulated glucagon responses in type 1 diabetes while liraglutide (a GLP-1 agonist) did not, demonstrating a unique mechanism among injectable diabetes therapies (Galderisi et al., 2018)
Adding pramlintide to closed-loop insulin delivery reduced mealtime glycemic excursions while allowing 10-20% insulin dose reductions, decreasing hypoglycemia risk (Sherr et al., 2016)
A co-formulation of pramlintide and insulin A21G (ADO09) reduced postprandial glucose increments by 69% compared to insulin aspart alone in a high-dose group in type 1 diabetes
Pramlintide requires separate injection from insulin due to pH incompatibility, which limits patient adherence; sustained-release depot formulations are in development (Tyagi et al., 2022)
The most common side effect is nausea, which typically diminishes over weeks; migraine-like attacks have been reported in a controlled provocation study (Ghanizada et al., 2021)

Why insulin alone is not enough

The postprandial glucose spike is driven by three simultaneous events: glucose absorption from the gut, hepatic glucose output stimulated by glucagon, and the rate at which food exits the stomach. Insulin addresses only the first by promoting glucose uptake into muscle, fat, and liver cells.

Aronoff (2017) outlined the rationale for targeting mealtime glucose specifically: postprandial glucose excursions contribute disproportionately to HbA1c in patients near their glycemic targets, and large glucose swings are associated with oxidative stress and cardiovascular risk independent of average glucose levels.^[1]

In healthy individuals, amylin co-secreted with insulin addresses the other two drivers. It suppresses inappropriate glucagon release from alpha cells after meals (glucagon stimulates the liver to produce more glucose, counteracting insulin's effects). It slows gastric emptying, moderating the rate at which dietary carbohydrates reach the bloodstream. And it acts on the area postrema in the brainstem to reduce meal size through satiety signaling.^[2]

People with type 1 diabetes produce no amylin. People with advanced type 2 diabetes produce inadequate amounts. Replacing insulin without replacing amylin leaves two of the three postprandial glucose control mechanisms unaddressed.

How pramlintide works: three mechanisms

Glucagon suppression

After a meal, glucagon should decrease to allow insulin to work unopposed. In diabetes, this suppression fails. Paradoxical postprandial glucagon elevation drives the liver to release glucose into the bloodstream at the exact time when dietary glucose is already flooding in.

Galderisi et al. (2018) published a direct comparison in type 1 diabetes patients: 3-4 weeks of pramlintide therapy suppressed meal-stimulated glucagon responses, while liraglutide (a GLP-1 receptor agonist) did not. This finding distinguishes pramlintide mechanistically from the GLP-1 drug class. Pramlintide acts through amylin receptors in the brain to suppress glucagon, a pathway that GLP-1 agonists do not effectively engage in the context of type 1 diabetes where beta cell-mediated paracrine signaling is absent.^[3]

Gastric emptying delay

Pramlintide slows the rate at which food moves from the stomach into the small intestine. This reduces the rate of glucose appearance in the bloodstream after a meal, effectively "smoothing" the postprandial glucose curve rather than creating a sharp spike that insulin must chase.

Hay et al. (2015) reviewed the evidence base: amylin and pramlintide delay gastric emptying through vagal afferent signaling from the area postrema, not through direct effects on the gastrointestinal tract. This centrally mediated mechanism is dose-dependent and reversible.^[2]

Asmar et al. (2010) investigated whether GLP-1's effects on gastric emptying involve amylin release and found that GLP-1 and amylin act through independent but complementary pathways. GLP-1 did not stimulate amylin secretion in humans, suggesting the two peptide systems operate in parallel rather than in series.^[4]

Satiety signaling

Boyle et al. (2018) reviewed amylin's role in both homeostatic and hedonic eating control. Amylin acts on neurons in the area postrema and nucleus of the solitary tract to reduce meal size. Pramlintide produces the same effect: patients taking pramlintide eat less per meal, leading to modest weight loss over time. This is pharmacologically distinct from the satiety effects of GLP-1 agonists, which act primarily through GLP-1 receptors in different brain regions.^[5]

The weight effect is clinically relevant because most insulin therapy causes weight gain. Pramlintide's satiety effect partially offsets insulin-associated weight gain, a combination benefit that insulin alone cannot provide.

Clinical evidence with insulin

Closed-loop insulin delivery

Sherr et al. (2016) tested pramlintide as an adjunct to closed-loop (artificial pancreas) insulin delivery. Closed-loop systems effectively maintain overnight glucose but struggle with meals because the insulin response to detected glucose rises is inherently delayed. Adding pramlintide (30 microg per meal) reduced mealtime glycemic excursions during closed-loop delivery while allowing 10-20% reductions in mealtime insulin doses.^[6]

The insulin dose reduction is a safety benefit: less insulin means less risk of hypoglycemia, which is the primary limiting factor in aggressive insulin dosing.

GLP-1 vs. amylin as insulin adjuncts

Renukuntla et al. (2014) directly compared GLP-1 analog (exenatide) and amylin analog (pramlintide) as adjunctive therapies to insulin in a closed-loop setting. Both reduced postprandial glucose excursions, but through different mechanisms. Pramlintide's glucagon suppression was more effective in type 1 diabetes, where the absence of beta cells limits GLP-1's ability to stimulate insulin secretion (since there are no functional beta cells to stimulate).^[7]

This mechanistic distinction matters for type 1 diabetes specifically: GLP-1 agonists' primary glucose-lowering mechanism (stimulating beta cell insulin secretion) is irrelevant when beta cells are destroyed. Pramlintide's mechanisms (glucagon suppression, gastric emptying, satiety) work independently of beta cell function.

ADO09: pramlintide-insulin co-formulation

One of the most significant recent developments is ADO09, a co-formulation of pramlintide with insulin A21G. In clinical testing, the high-dose group showed a 69% reduction in postprandial glucose increments from 0 to 4 hours compared to insulin aspart alone. A 20% reduction in prandial insulin doses was needed with ADO09, but no change in basal insulin requirements. This co-formulation addresses the major practical barrier of pramlintide therapy: the need for a separate injection.

Pramlintide's molecular design

Pramlintide is a 37-amino acid peptide that closely mimics human amylin but with three proline substitutions (at positions 25, 28, and 29). These substitutions were engineered to solve a critical problem: human amylin spontaneously aggregates into amyloid fibrils, which is both a manufacturing challenge and a pathological feature of type 2 diabetes (islet amyloid deposits are found in the pancreas of most T2D patients).

Wang et al. (2015) analyzed how pramlintide's proline substitutions inhibit amyloid formation while preserving receptor binding. The prolines disrupt beta-sheet formation, which is the structural basis of amyloid fibril assembly, without altering the peptide's ability to activate amylin receptors. The balance between maintaining biological activity and reducing amyloidogenicity was the central design challenge.^[8]

Bower and Hay (2016) reviewed amylin structure-function relationships and receptor pharmacology. Amylin receptors are heterodimers composed of the calcitonin receptor (CTR) combined with receptor activity-modifying proteins (RAMPs). Different CTR/RAMP combinations produce receptor subtypes with distinct pharmacology, which has implications for next-generation amylin analogs being designed for improved selectivity.^[9]

Practical limitations

Separate injection requirement

Pramlintide cannot be mixed with insulin in the same syringe because of pH incompatibility: pramlintide is formulated at pH 4.0, while insulin analogs are formulated at pH 7.0-7.4. This means patients must give two separate injections before each meal, tripling the injection burden for someone already taking mealtime insulin. This is widely cited as the primary reason pramlintide has not achieved broader adoption despite demonstrated glycemic benefits.

Nausea

Nausea is the most common side effect, affecting approximately 30-50% of patients at treatment initiation. It is dose-dependent and typically resolves within weeks as the body adjusts. The mechanism is related to pramlintide's central action on the area postrema, the same brain region responsible for its therapeutic effects on gastric emptying and satiety.

Migraine

Ghanizada et al. (2021) reported that pramlintide infusion induced migraine-like attacks in migraine patients in a controlled provocation study. This finding connects amylin signaling to migraine pathophysiology through the calcitonin receptor family (amylin receptors share structural components with CGRP receptors, and CGRP is a validated migraine target). Whether subcutaneous pramlintide at therapeutic doses produces clinically meaningful migraine worsening in routine use remains unclear from this provocation model.^[10]

Next-generation delivery approaches

The injection burden has driven research into alternative delivery methods.

Tyagi et al. (2022) developed an injectable biodegradable silica depot that sustained pramlintide release for two months. The depot formulation maintained blood glucose lowering effects in animal models while eliminating the need for multiple daily injections. If translated to clinical use, a monthly or bimonthly depot injection would fundamentally change the practical calculus of pramlintide therapy.^[11]

Bottger et al. (2018) explored PEGylation of both amylin and GLP-1 peptides as a strategy to extend half-life and reduce injection frequency. PEGylated amylin prodrugs maintained biological activity while achieving sustained plasma levels, suggesting that longer-acting amylin analogs are pharmacologically feasible.^[12]

The co-formulation approach (ADO09) represents a third strategy: rather than extending pramlintide's duration, combine it with insulin in a single injection to eliminate the separate-injection barrier.

Where pramlintide fits in the treatment landscape

Pramlintide occupies a unique pharmacological niche. It is the only approved drug that replaces amylin function. GLP-1 agonists share some overlapping effects (gastric emptying delay, satiety) but work through different receptors and do not suppress glucagon as effectively in type 1 diabetes.^[3]

For type 1 diabetes, pramlintide addresses a genuine physiological deficit: the complete absence of amylin. Why amylin replacement makes biological sense for type 1 diabetes is covered in the dedicated article.

For type 2 diabetes, pramlintide competes with GLP-1 agonists that offer once-weekly dosing, greater weight loss, and cardiovascular outcome data. The practical advantages of GLP-1 receptor agonists have largely overshadowed pramlintide in type 2 diabetes management, despite pramlintide's distinct mechanism.

The development of co-formulations, depot formulations, and combination amylin-GLP-1 analogs may eventually shift this dynamic by making amylin replacement more practical for routine clinical use.

The Bottom Line

Pramlintide fills a specific gap in diabetes management that insulin alone cannot address. It suppresses postprandial glucagon, slows gastric emptying, and promotes satiety through amylin receptor activation in the brain. Clinical data confirms that these effects reduce postprandial glucose spikes and allow lower insulin doses. The requirement for separate injections before each meal has limited adoption despite clear efficacy. Co-formulations with insulin, sustained-release depots, and PEGylated analogs are all under development to overcome this barrier.

Frequently Asked Questions

Pramlintide reduces postprandial blood sugar spikes through three mechanisms: it suppresses glucagon release from the pancreas (which otherwise tells the liver to dump glucose after meals), slows gastric emptying (reducing the rate carbohydrates enter the bloodstream), and promotes satiety (reducing meal size). Galderisi et al. (2018) showed that pramlintide uniquely suppresses meal-stimulated glucagon in type 1 diabetes, an effect that GLP-1 agonists like liraglutide do not achieve.

Insulin lowers blood sugar by driving glucose into cells. Pramlintide works through completely different mechanisms: it stops the liver from releasing extra glucose (by suppressing glucagon), slows food leaving the stomach, and reduces appetite. Pramlintide is a synthetic version of amylin, a hormone that healthy beta cells co-secrete with insulin. In diabetes, both hormones are deficient, but standard treatment only replaces insulin. Pramlintide replaces the missing amylin component.

The primary barrier is the injection burden. Pramlintide cannot be mixed with insulin due to pH incompatibility, requiring a separate subcutaneous injection before each meal. For someone already injecting mealtime insulin three times daily, pramlintide triples the injection count. Nausea at treatment initiation affects 30-50% of patients. GLP-1 agonists with once-weekly dosing have also captured much of the market for adjunctive glucose control in type 2 diabetes.

Pramlintide has been studied as an adjunct to closed-loop insulin delivery (artificial pancreas systems). Sherr et al. (2016) showed that adding pramlintide to closed-loop insulin delivery reduced mealtime glucose spikes while allowing 10-20% lower insulin doses. However, pramlintide currently requires a separate injection and cannot be delivered through the same pump as insulin. Co-formulations like ADO09, which combine pramlintide with insulin in a single solution, are in clinical development.

The most common side effect is nausea, affecting 30-50% of patients initially but typically resolving within weeks. This is related to pramlintide's action on the area postrema in the brainstem. Ghanizada et al. (2021) reported that pramlintide infusion can trigger migraine-like attacks in migraine patients through activation of the calcitonin receptor family. Hypoglycemia risk can increase when pramlintide is added to insulin therapy, which is why insulin doses are typically reduced by 50% when starting pramlintide.

Pramlintide is a synthetic analog of human amylin, not identical to it. Human amylin spontaneously aggregates into amyloid fibrils, which creates manufacturing problems and is associated with beta cell damage in type 2 diabetes. Pramlintide has three proline substitutions at positions 25, 28, and 29 that prevent this aggregation while preserving the ability to activate amylin receptors. Wang et al. (2015) analyzed how these substitutions balance amyloid prevention with receptor binding activity.